KAINOS MEDICINE - Key Persons
Dr. Carrolee Barlow is a world-renowned neurodegeneration expert, working as the CEO of Parkinson Research Center in California. Dr. Barlow is an expert in patient treatment, fundamental research and clinical trials; she was once a professor at Salk Institute for Biological Studies. Afterwards, she was Director and Manager of the Neuroscience department at Merck. Dr. Barlow received a Doctorate degree on molecular gerontology from Karolinska Medical Nobel Institute in Sweden, a medical Doctor degree From Utah University, and finished her residency at Cornell Medical Center.
Dr. M.C. Kang has experience in new drug discovery at Global Pharmaceutical and Venture companies. He is developed and released Fuzeon of AIDS drug as Chief vice president in Trimeris of Venture Company in the United States (1995-2003). He had an experience for successful IPO in NASQ. Dr. M.C. kang earned his Ph.D. in organic chemistry at Oregon University after receiving B.S. in Chemistry at Sogang University in 1975. After a postdoctoral fellowship at Harvard University, he worked in GSK as a Director in Medicinal Chemistry.
K.S. Lee co-founded Silicon Image, Inc. in Silicon Valley, U.S. a developer of semiconductors for communications applications in 1994, and served as the Vice President of Strategic Alliance. He had an experience for successful IPO of Silicon Image in 1999. After that, he was the founding CEO of GCT Semiconductor, a fabless semiconductor company in the United States that designs, develops, and markets innovative integrated circuit solutions for the wireless communications industry. He graduated from electrical engineering department at Hanyang University.
K.S. Lee co-founded Silicon Image, Inc. in Silicon Valley, U.S. a developer of semiconductors for communications applications in 1994, and served as the Vice President of Strategic Alliance. He had an experience for successful IPO of Silicon Image in 1999. After that, he was the founding CEO of GCT Semiconductor, a fabless semiconductor company in the United States that designs, develops, and markets innovative integrated circuit solutions for the wireless communications industry. He graduated from electrical engineering department in Hanyang University.
Presently In Chull Kim is President of Corporate Strategy, Kainos Medicine. From 2011 up to 2017 he had been the CEO & President, National OncoVenture that was anti-cancer new drug development program sponsored by Korean government. From 1993 to 2011 he had been at various director's positions and also served as the CEO & President of LG Life Sciences. In 1985 he had received his Ph.D. degree from University of Illinois, since then he worked as the research fellow at the Rockefeller University and Duke Medical Center. Prior to coming back to Korea in 1993 he worked as the Research Investigator at the Glaxo, Inc., USA.
Dr. Lee earned his Ph.D. in Biochemistry/Genetics at Duke University in 1989 after receiving MS at KAIST and B.S. in Biology at Sogang University in Seoul. After postdoctoral training under Dr. Arno Greenleaf in Biochemistry at Duke University, he was a research assistant professor jointly under Dr. Robert Lefkowitz (2012 Nobel Prize Laureate) and Dr. Marc Caron in Cell Biology at Duke University. Then, he moved to pharmaceutical industry and worked for ACLARA Biosciences, EXELIXIS Pharmaceuticals, and ARAGEN Bioscience in US for 14 years. While in EXELIXIS for 10 years, he was a key contributor and project leader that implemented 8 pipelines of cancer drugs, including drugs targeting protein kinases, and anti-metabolic drugs. Also, he has experienced in ARAGEN with developing anti-cancer biotherapeutic drugs such as cancer vaccines, monoclonal antibodies and complex immunotoxin therapeutics. As the VP of Biology, he is currently focusing on the clinical development of KM-819 for Parkinson's disease. Also, as a Chief Business Officer, he has been working on licensing and other company business.
Job Titles:
- Director of the Center for Integrative Chemical Biology
Stephen Frye is the Director of the Center for Integrative Chemical Biology and Drug Discovery and a Research Professor within the Medicinal Chemistry and Natural Products Division in the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. Stephen was previously the World-wide Vice President of Discovery Medicinal Chemistry at GlaxoSmithKline where he directed all hit to lead discovery activities for the company. While at GSK, Stephen invented Avodart, a dual 5 alpha-reductase inhibitor marketed to treat prostatic disease. He also created a global kinase chemistry team that discovered Tykerb (metastatic breast cancer) and Pazopanib (renal carcinoma). He received his Ph.D. in organic chemistry from the University of North Carolina in 1987. Stephen has more than 50 patents and publications.
Job Titles:
- CEO of HI Investment & Securities
Suh Tae hwan is the CEO of HI Investment & Securities (CJ Investment & Securities), Executive Director of Financial and Accounting of HYUNDAI Heavy Industries and Director General for International Sales and Financial Services of Hyundai Securities. He worked Outside Director of Hyundai Mipo Dockyard, Hyundai Samho and Hyundai Oil bank. He received a bachelor's degree in Business Administration from Seoul National University and MBA in Wharton School of the University of Pennsylvania.